Unicef

EMA authorizes Bavarian Nordic's mpox vaccine Imvanex for adolescents; WHO supports single-dose use for wider reach. CHMP recommends updated mRNA COVID-19 vaccines and approves 8 new medicines, extends 11 others.

UNAIDS Executive Director Winnie Byanyima urges world leaders to make new HIV prevention technologies, like the 100% effective lenacapavir, available and affordable, and to revitalize multilateralism to end AIDS by 2030.

WHO approved Bavarian Nordic's MVA-BN mpox vaccine for adults, with conditional use for babies, children, teens, and pregnant women in outbreak settings. Critics argue the vaccine's safety and efficacy in pediatric populations are unproven, questioning WHO's approval. The vaccine, sold as Jynneos in the US, is also criticized for diverting resources from broader public health issues in Africa.

DOH warns against unauthorized mpox vaccines; WHO prequalifies MVA-BN vaccine for mpox, emphasizing urgent scale-up for equitable access.

WHO prequalified Bavarian Nordic's mpox vaccine for use in affected regions, aiming to reduce transmission and contain outbreaks. The MVA-BN vaccine, for ages 18 and above, requires two doses four weeks apart and can be stored at 2-8°C for up to 8 weeks. This approval is expected to expedite procurement and distribution by governments and international agencies.

WHO prequalifies MVA-BN as first mpox vaccine, aiming to expedite access and control outbreaks. The vaccine, for those over 18, requires two doses four weeks apart and can be stored at 2–8°C for up to eight weeks. This decision aids in fast-tracking approvals and procurement by governments and international agencies.

WHO prequalifies MVA-BN vaccine for mpox, facilitating increased access to combat outbreaks. The vaccine, administered in two doses four weeks apart, has an estimated 82% effectiveness. WHO emphasizes the need for urgent scale-up in procurement and distribution to ensure equitable access, especially in Africa.

WHO approved MVA-BN mpox vaccine for first time, aiming to facilitate timely access for millions at risk in Africa. The vaccine, already approved in Europe and the US, can be administered in two doses with 82% effectiveness. WHO's prequalification aims to accelerate procurement and regulatory approval worldwide.

WHO approves MVA-BN as first pre-qualified mpox vaccine, with single-dose effectiveness at 76% and two-dose at 82%. WHO chief emphasizes urgent vaccine procurement and roll-out for equitable access.